ticker	title	link	topic	published_est	market	hour_of_day
"PHIL.MI"	"Philogen provides update on pre-planned interim analysis of the Phase III FIBROSARC trial investigating Onfekafusp alfa (L19TNF) in patients with first-line advanced or metastatic Soft Tissue Sarcoma"	"https://www.globenewswire.com/news-release/2024/02/20/2831505/0/en/Philogen-provides-update-on-pre-planned-interim-analysis-of-the-Phase-III-FIBROSARC-trial-investigating-Onfekafusp-alfa-L19TNF-in-patients-with-first-line-advanced-or-metastatic-So.html"	"research_analysis_and_reports"	"2024-02-20 01:30:00"	"overnight"	1
"MDG1.DE"	"Medigene to Present at Upcoming Conferences"	"https://www.globenewswire.com/news-release/2024/02/19/2831266/0/en/Medigene-to-Present-at-Upcoming-Conferences.html"	"company_announcement"	"2024-02-19 08:00:00"	"pre_market"	8
"GMAB"	"Transactions in connection with share buy-back program"	"https://www.globenewswire.com/news-release/2024/02/19/2831158/0/en/Transactions-in-connection-with-share-buy-back-program.html"	"european_regulatory_news"	"2024-02-19 04:40:00"	"pre_market"	4
"IOVA"	"Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)"	"https://www.globenewswire.com/news-release/2024/02/16/2830967/0/en/Iovance-Biotherapeutics-Reports-Inducement-Grants-under-NASDAQ-Listing-Rule-5635-c-4.html"	"Changes in company's own shares"	"2024-02-16 17:30:00"	"after_hours"	17
"IOVA"	"Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)"	"https://www.globenewswire.com/news-release/2024/02/16/2830967/0/en/Iovance-Biotherapeutics-Reports-Inducement-Grants-under-NASDAQ-Listing-Rule-5635-c-4.html"	"changes_in_company's_own_shares"	"2024-02-16 17:30:00"	"after_hours"	17
"IOVA"	"Iovance Biotherapeutics to Host Conference Call and Webcast on Friday, February 16, 2024"	"https://www.globenewswire.com/news-release/2024/02/16/2830926/0/en/Iovance-Biotherapeutics-to-Host-Conference-Call-and-Webcast-on-Friday-February-16-2024.html"	"Conference Calls/ Webcasts"	"2024-02-16 15:38:00"	"market_open"	15
"IOVA"	"Iovance Biotherapeutics to Host Conference Call and Webcast on Friday, February 16, 2024"	"https://www.globenewswire.com/news-release/2024/02/16/2830926/0/en/Iovance-Biotherapeutics-to-Host-Conference-Call-and-Webcast-on-Friday-February-16-2024.html"	"conference_calls__webcasts"	"2024-02-16 15:38:00"	"market_open"	15
"IOVA"	"Iovance’s AMTAGVI™ (lifileucel) Receives U.S. FDA Accelerated Approval for Advanced Melanoma"	"https://www.globenewswire.com/news-release/2024/02/16/2830923/0/en/Iovance-s-AMTAGVI-lifileucel-Receives-U-S-FDA-Accelerated-Approval-for-Advanced-Melanoma.html"	"Product / Services Announcement"	"2024-02-16 15:19:00"	"market_open"	15
"IOVA"	"Iovance’s AMTAGVI™ (lifileucel) Receives U.S. FDA Accelerated Approval for Advanced Melanoma"	"https://www.globenewswire.com/news-release/2024/02/16/2830923/0/en/Iovance-s-AMTAGVI-lifileucel-Receives-U-S-FDA-Accelerated-Approval-for-Advanced-Melanoma.html"	"product___services_announcement"	"2024-02-16 15:19:00"	"market_open"	15
"ICCC"	"ImmuCell to Announce Unaudited Financial Results for the Quarter and Year Ended December 31, 2023"	"https://www.globenewswire.com/news-release/2024/02/16/2830814/0/en/ImmuCell-to-Announce-Unaudited-Financial-Results-for-the-Quarter-and-Year-Ended-December-31-2023.html"	"conference_calls__webcasts"	"2024-02-16 09:30:00"	"market_open"	9
"ICCC"	"ImmuCell to Announce Unaudited Financial Results for the Quarter and Year Ended December 31, 2023"	"https://www.globenewswire.com/news-release/2024/02/16/2830814/0/en/ImmuCell-to-Announce-Unaudited-Financial-Results-for-the-Quarter-and-Year-Ended-December-31-2023.html"	"Conference Calls/ Webcasts"	"2024-02-16 09:30:00"	"market_open"	9
"MDXH"	"Mdxhealth Announces Resignation of Board Member"	"https://www.globenewswire.com/news-release/2024/02/16/2830770/0/en/Mdxhealth-Announces-Resignation-of-Board-Member.html"	"directors_and_officers"	"2024-02-16 08:45:00"	"pre_market"	8
"MDXH"	"Mdxhealth Announces Resignation of Board Member"	"https://www.globenewswire.com/news-release/2024/02/16/2830770/0/en/Mdxhealth-Announces-Resignation-of-Board-Member.html"	"Directors and Officers"	"2024-02-16 08:45:00"	"pre_market"	8
"ARQT"	"Arcutis to Report Fourth Quarter and Full Year 2023 Financial Results"	"https://www.globenewswire.com/news-release/2024/02/16/2830722/0/en/Arcutis-to-Report-Fourth-Quarter-and-Full-Year-2023-Financial-Results.html"	"calendar_of_events"	"2024-02-16 08:00:00"	"pre_market"	8
"ARQT"	"Arcutis to Report Fourth Quarter and Full Year 2023 Financial Results"	"https://www.globenewswire.com/news-release/2024/02/16/2830722/0/en/Arcutis-to-Report-Fourth-Quarter-and-Full-Year-2023-Financial-Results.html"	"Calendar of Events"	"2024-02-16 08:00:00"	"pre_market"	8
"OCUP"	"Ocuphire Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)"	"https://www.globenewswire.com/news-release/2024/02/15/2830386/0/en/Ocuphire-Pharma-Reports-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html"	"Product / Services Announcement"	"2024-02-15 16:10:00"	"after_hours"	16
"OCUP"	"Ocuphire Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)"	"https://www.globenewswire.com/news-release/2024/02/15/2830386/0/en/Ocuphire-Pharma-Reports-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html"	"product___services_announcement"	"2024-02-15 16:10:00"	"after_hours"	16
"TTOO"	"T2 Biosystems Announces Preliminary Fourth Quarter and Full Year 2023 Financial Results"	"https://www.globenewswire.com/news-release/2024/02/15/2830381/32489/en/T2-Biosystems-Announces-Preliminary-Fourth-Quarter-and-Full-Year-2023-Financial-Results.html"	"Pre-Release Comments"	"2024-02-15 16:06:00"	"after_hours"	16
"TTOO"	"T2 Biosystems Announces Preliminary Fourth Quarter and Full Year 2023 Financial Results"	"https://www.globenewswire.com/news-release/2024/02/15/2830381/32489/en/T2-Biosystems-Announces-Preliminary-Fourth-Quarter-and-Full-Year-2023-Financial-Results.html"	"pre-release_comments"	"2024-02-15 16:06:00"	"after_hours"	16
"QGEN"	"QIAGEN earns ACT Label for new eco-friendlier QIAwave products and achieves first My Green Lab Platinum certification"	"https://www.globenewswire.com/news-release/2024/02/15/2830368/8690/en/QIAGEN-earns-ACT-Label-for-new-eco-friendlier-QIAwave-products-and-achieves-first-My-Green-Lab-Platinum-certification.html"	"company_announcement"	"2024-02-15 16:05:00"	"after_hours"	16
"PCVX"	"Vaxcyte to Report Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024"	"https://www.globenewswire.com/news-release/2024/02/15/2830367/0/en/Vaxcyte-to-Report-Fourth-Quarter-and-Full-Year-2023-Financial-Results-on-February-27-2024.html"	"conference_calls__webcasts"	"2024-02-15 16:05:00"	"after_hours"	16
"PCVX"	"Vaxcyte to Report Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024"	"https://www.globenewswire.com/news-release/2024/02/15/2830367/0/en/Vaxcyte-to-Report-Fourth-Quarter-and-Full-Year-2023-Financial-Results-on-February-27-2024.html"	"Conference Calls/ Webcasts"	"2024-02-15 16:05:00"	"after_hours"	16
"QGEN"	"QIAGEN erhält ACT-Label für neue, umweltfreundlichere QIAwave?Produkte und erste Platin-Zertifizierung von My Green Lab"	"https://www.globenewswire.com/news-release/2024/02/15/2830366/0/de/QIAGEN-erh%C3%A4lt-ACT-Label-f%C3%BCr-neue-umweltfreundlichere-QIAwave-Produkte-und-erste-Platin-Zertifizierung-von-My-Green-Lab.html"	"product___services_announcement"	"2024-02-15 16:05:00"	"after_hours"	16
"QGEN"	"QIAGEN erhält ACT-Label für neue, umweltfreundlichere QIAwave?Produkte und erste Platin-Zertifizierung von My Green Lab"	"https://www.globenewswire.com/news-release/2024/02/15/2830366/0/de/QIAGEN-erh%C3%A4lt-ACT-Label-f%C3%BCr-neue-umweltfreundlichere-QIAwave-Produkte-und-erste-Platin-Zertifizierung-von-My-Green-Lab.html"	"Product / Services Announcement"	"2024-02-15 16:05:00"	"after_hours"	16
"QGEN"	"QIAGEN earns ACT Label for new eco-friendlier QIAwave products and achieves first My Green Lab Platinum certification"	"https://www.globenewswire.com/news-release/2024/02/15/2830368/8690/en/QIAGEN-earns-ACT-Label-for-new-eco-friendlier-QIAwave-products-and-achieves-first-My-Green-Lab-Platinum-certification.html"	"Company Announcement"	"2024-02-15 16:05:00"	"after_hours"	16
"TTOO"	"T2 Biosystems Announces Agreement with CRG for the Conversion of $15 Million of CRG Term Loan into Equity"	"https://www.globenewswire.com/news-release/2024/02/15/2830361/32489/en/T2-Biosystems-Announces-Agreement-with-CRG-for-the-Conversion-of-15-Million-of-CRG-Term-Loan-into-Equity.html"	"financing_agreements"	"2024-02-15 16:04:00"	"after_hours"	16
"TTOO"	"T2 Biosystems Announces Agreement with CRG for the Conversion of $15 Million of CRG Term Loan into Equity"	"https://www.globenewswire.com/news-release/2024/02/15/2830361/32489/en/T2-Biosystems-Announces-Agreement-with-CRG-for-the-Conversion-of-15-Million-of-CRG-Term-Loan-into-Equity.html"	"Financing Agreements"	"2024-02-15 16:04:00"	"after_hours"	16
"SWAV"	"Shockwave Medical Reports Fourth Quarter and Full Year 2023 Financial Results"	"https://www.globenewswire.com/news-release/2024/02/15/2830359/0/en/Shockwave-Medical-Reports-Fourth-Quarter-and-Full-Year-2023-Financial-Results.html"	"earnings_releases_and_operating_results"	"2024-02-15 16:03:00"	"after_hours"	16
"SWAV"	"Shockwave Medical Reports Fourth Quarter and Full Year 2023 Financial Results"	"https://www.globenewswire.com/news-release/2024/02/15/2830359/0/en/Shockwave-Medical-Reports-Fourth-Quarter-and-Full-Year-2023-Financial-Results.html"	"Earnings Releases and Operating Results"	"2024-02-15 16:03:00"	"after_hours"	16
"TTOO"	"T2 Biosystems Announces Commercial Expansion Through Distributors in Europe and Asia"	"https://www.globenewswire.com/news-release/2024/02/15/2830354/32489/en/T2-Biosystems-Announces-Commercial-Expansion-Through-Distributors-in-Europe-and-Asia.html"	"business_contracts"	"2024-02-15 16:02:00"	"after_hours"	16
"TTOO"	"T2 Biosystems Announces Commercial Expansion Through Distributors in Europe and Asia"	"https://www.globenewswire.com/news-release/2024/02/15/2830354/32489/en/T2-Biosystems-Announces-Commercial-Expansion-Through-Distributors-in-Europe-and-Asia.html"	"Business Contracts"	"2024-02-15 16:02:00"	"after_hours"	16
"TSHA"	"Taysha Gene Therapies Provides Update on Deprioritized Pipeline Programs"	"https://www.globenewswire.com/news-release/2024/02/15/2830347/0/en/Taysha-Gene-Therapies-Provides-Update-on-Deprioritized-Pipeline-Programs.html"	"Management statements"	"2024-02-15 16:01:00"	"after_hours"	16
"GLPG"	"Galapagos presenteert op de jaarlijkse EBMT-EHA meeting van 2024"	"https://www.globenewswire.com/news-release/2024/02/15/2830350/0/nl/Galapagos-presenteert-op-de-jaarlijkse-EBMT-EHA-meeting-van-2024.html"	"European Regulatory News"	"2024-02-15 16:01:00"	"after_hours"	16
"GLPG"	"Galapagos presents at EBMT-EHA annual meeting 2024"	"https://www.globenewswire.com/news-release/2024/02/15/2830350/0/en/Galapagos-presents-at-EBMT-EHA-annual-meeting-2024.html"	"european_regulatory_news"	"2024-02-15 16:01:00"	"after_hours"	16
"GLPG"	"Galapagos presenteert op de jaarlijkse EBMT-EHA meeting van 2024"	"https://www.globenewswire.com/news-release/2024/02/15/2830350/0/nl/Galapagos-presenteert-op-de-jaarlijkse-EBMT-EHA-meeting-van-2024.html"	"european_regulatory_news"	"2024-02-15 16:01:00"	"after_hours"	16
"TSHA"	"Taysha Gene Therapies Provides Update on Deprioritized Pipeline Programs"	"https://www.globenewswire.com/news-release/2024/02/15/2830347/0/en/Taysha-Gene-Therapies-Provides-Update-on-Deprioritized-Pipeline-Programs.html"	"management_statements"	"2024-02-15 16:01:00"	"after_hours"	16
"GLPG"	"Galapagos presents at EBMT-EHA annual meeting 2024"	"https://www.globenewswire.com/news-release/2024/02/15/2830350/0/en/Galapagos-presents-at-EBMT-EHA-annual-meeting-2024.html"	"European Regulatory News"	"2024-02-15 16:01:00"	"after_hours"	16
"RENB"	"Cutting Edge AI Company GEDiCube and Cyclomics sign binding LOI to join forces and position themselves at the forefront of the global liquid biopsy marketplace"	"https://www.globenewswire.com/news-release/2024/02/15/2830059/0/en/Cutting-Edge-AI-Company-GEDiCube-and-Cyclomics-sign-binding-LOI-to-join-forces-and-position-themselves-at-the-forefront-of-the-global-liquid-biopsy-marketplace.html"	"Mergers and Acquisitions"	"2024-02-15 09:25:00"	"overnight"	9
"RENB"	"Cutting Edge AI Company GEDiCube and Cyclomics sign binding LOI to join forces and position themselves at the forefront of the global liquid biopsy marketplace"	"https://www.globenewswire.com/news-release/2024/02/15/2830059/0/en/Cutting-Edge-AI-Company-GEDiCube-and-Cyclomics-sign-binding-LOI-to-join-forces-and-position-themselves-at-the-forefront-of-the-global-liquid-biopsy-marketplace.html"	"mergers_and_acquisitions"	"2024-02-15 09:25:00"	"overnight"	9
"PCRX"	"Pacira Announces Publication of Pivotal Study of EXPAREL as a Sciatic Nerve Block in the Popliteal Fossa for Patients After Bunionectomy"	"https://www.globenewswire.com/news-release/2024/02/15/2829981/0/en/Pacira-Announces-Publication-of-Pivotal-Study-of-EXPAREL-as-a-Sciatic-Nerve-Block-in-the-Popliteal-Fossa-for-Patients-After-Bunionectomy.html"	"Clinical Study"	"2024-02-15 08:36:00"	"pre_market"	8
"PCRX"	"Pacira Announces Publication of Pivotal Study of EXPAREL as a Sciatic Nerve Block in the Popliteal Fossa for Patients After Bunionectomy"	"https://www.globenewswire.com/news-release/2024/02/15/2829981/0/en/Pacira-Announces-Publication-of-Pivotal-Study-of-EXPAREL-as-a-Sciatic-Nerve-Block-in-the-Popliteal-Fossa-for-Patients-After-Bunionectomy.html"	"clinical_study"	"2024-02-15 08:36:00"	"pre_market"	8
"CRSP"	"CRISPR Therapeutics to Present at the Citi 2024 Virtual Oncology Leadership Summit"	"https://www.globenewswire.com/news-release/2024/02/15/2829970/0/en/CRISPR-Therapeutics-to-Present-at-the-Citi-2024-Virtual-Oncology-Leadership-Summit.html"	"Calendar of Events"	"2024-02-15 08:30:00"	"pre_market"	8
"GTHX"	"G1 Therapeutics to Release Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on February 28, 2024"	"https://www.globenewswire.com/news-release/2024/02/15/2829974/0/en/G1-Therapeutics-to-Release-Fourth-Quarter-and-Full-Year-2023-Financial-Results-and-Provide-Business-Update-on-February-28-2024.html"	"Conference Calls/ Webcasts"	"2024-02-15 08:30:00"	"pre_market"	8
"GTHX"	"G1 Therapeutics to Release Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on February 28, 2024"	"https://www.globenewswire.com/news-release/2024/02/15/2829974/0/en/G1-Therapeutics-to-Release-Fourth-Quarter-and-Full-Year-2023-Financial-Results-and-Provide-Business-Update-on-February-28-2024.html"	"conference_calls__webcasts"	"2024-02-15 08:30:00"	"pre_market"	8
"CRSP"	"CRISPR Therapeutics to Present at the Citi 2024 Virtual Oncology Leadership Summit"	"https://www.globenewswire.com/news-release/2024/02/15/2829970/0/en/CRISPR-Therapeutics-to-Present-at-the-Citi-2024-Virtual-Oncology-Leadership-Summit.html"	"calendar_of_events"	"2024-02-15 08:30:00"	"pre_market"	8
"AMRN"	"Amarin to Report Fourth Quarter and Full Year 2023 Financial Results and Host Conference on February 29, 2024"	"https://www.globenewswire.com/news-release/2024/02/15/2829894/18362/en/Amarin-to-Report-Fourth-Quarter-and-Full-Year-2023-Financial-Results-and-Host-Conference-on-February-29-2024.html"	"conference_calls__webcasts"	"2024-02-15 08:00:00"	"pre_market"	8
"AMRN"	"Amarin to Report Fourth Quarter and Full Year 2023 Financial Results and Host Conference on February 29, 2024"	"https://www.globenewswire.com/news-release/2024/02/15/2829894/18362/en/Amarin-to-Report-Fourth-Quarter-and-Full-Year-2023-Financial-Results-and-Host-Conference-on-February-29-2024.html"	"Conference Calls/ Webcasts"	"2024-02-15 08:00:00"	"pre_market"	8
"NTLA"	"Intellia Therapeutics and ReCode Therapeutics Announce Strategic Collaboration to Develop Novel Gene Editing Therapies for Cystic Fibrosis"	"https://www.globenewswire.com/news-release/2024/02/15/2829852/0/en/Intellia-Therapeutics-and-ReCode-Therapeutics-Announce-Strategic-Collaboration-to-Develop-Novel-Gene-Editing-Therapies-for-Cystic-Fibrosis.html"	"partnerships"	"2024-02-15 07:30:00"	"pre_market"	7
"NTLA"	"Intellia Therapeutics and ReCode Therapeutics Announce Strategic Collaboration to Develop Novel Gene Editing Therapies for Cystic Fibrosis"	"https://www.globenewswire.com/news-release/2024/02/15/2829852/0/en/Intellia-Therapeutics-and-ReCode-Therapeutics-Announce-Strategic-Collaboration-to-Develop-Novel-Gene-Editing-Therapies-for-Cystic-Fibrosis.html"	"Partnerships"	"2024-02-15 07:30:00"	"pre_market"	7
"ALVO"	"Alvotech Announces Expected Global Market Entry Dates for AVT04 Biosimilar to Stelara® (ustekinumab)"	"https://www.globenewswire.com/news-release/2024/02/15/2829779/0/en/Alvotech-Announces-Expected-Global-Market-Entry-Dates-for-AVT04-Biosimilar-to-Stelara-ustekinumab.html"	"Financing Agreements"	"2024-02-15 06:30:00"	"pre_market"	6
"ALVO"	"Alvotech tilkynnir hvenær sala á AVT04, líftæknilyfjahliðstæðu við Stelara, getur hafist á alþjóðlegum mörkuðum"	"https://www.globenewswire.com/news-release/2024/02/15/2829780/0/is/Alvotech-tilkynnir-hven%C3%A6r-sala-%C3%A1-AVT04-l%C3%ADft%C3%A6knilyfjahli%C3%B0st%C3%A6%C3%B0u-vi%C3%B0-Stelara-getur-hafist-%C3%A1-al%C3%BEj%C3%B3%C3%B0legum-m%C3%B6rku%C3%B0um.html"	"European Regulatory News"	"2024-02-15 06:30:00"	"pre_market"	6
"ALVO"	"Alvotech Announces Expected Global Market Entry Dates for AVT04 Biosimilar to Stelara® (ustekinumab)"	"https://www.globenewswire.com/news-release/2024/02/15/2829780/0/en/Alvotech-Announces-Expected-Global-Market-Entry-Dates-for-AVT04-Biosimilar-to-Stelara-ustekinumab.html"	"european_regulatory_news"	"2024-02-15 06:30:00"	"pre_market"	6
"ALVO"	"Alvotech Announces Expected Global Market Entry Dates for AVT04 Biosimilar to Stelara® (ustekinumab)"	"https://www.globenewswire.com/news-release/2024/02/15/2829780/0/en/Alvotech-Announces-Expected-Global-Market-Entry-Dates-for-AVT04-Biosimilar-to-Stelara-ustekinumab.html"	"European Regulatory News"	"2024-02-15 06:30:00"	"pre_market"	6
"ALVO"	"Alvotech tilkynnir hvenær sala á AVT04, líftæknilyfjahliðstæðu við Stelara, getur hafist á alþjóðlegum mörkuðum"	"https://www.globenewswire.com/news-release/2024/02/15/2829780/0/is/Alvotech-tilkynnir-hven%C3%A6r-sala-%C3%A1-AVT04-l%C3%ADft%C3%A6knilyfjahli%C3%B0st%C3%A6%C3%B0u-vi%C3%B0-Stelara-getur-hafist-%C3%A1-al%C3%BEj%C3%B3%C3%B0legum-m%C3%B6rku%C3%B0um.html"	"european_regulatory_news"	"2024-02-15 06:30:00"	"pre_market"	6
"ALVO"	"Alvotech Announces Expected Global Market Entry Dates for AVT04 Biosimilar to Stelara® (ustekinumab)"	"https://www.globenewswire.com/news-release/2024/02/15/2829779/0/en/Alvotech-Announces-Expected-Global-Market-Entry-Dates-for-AVT04-Biosimilar-to-Stelara-ustekinumab.html"	"financing_agreements"	"2024-02-15 06:30:00"	"pre_market"	6
"GMAB"	"Notice to Convene the Annual General Meeting of Genmab A/S"	"https://www.globenewswire.com/news-release/2024/02/15/2829756/0/en/Notice-to-Convene-the-Annual-General-Meeting-of-Genmab-A-S.html"	"European Regulatory News"	"2024-02-15 06:00:00"	"pre_market"	6
"GMAB"	"Notice to Convene the Annual General Meeting of Genmab A/S"	"https://www.globenewswire.com/news-release/2024/02/15/2829756/0/en/Notice-to-Convene-the-Annual-General-Meeting-of-Genmab-A-S.html"	"european_regulatory_news"	"2024-02-15 06:00:00"	"pre_market"	6
"VALN"	"Valneva publie son chiffre d’affaires et sa trésorerie pour l’exercice 2023 et fournit des indications préliminaires pour l’exercice 2024"	"https://www.globenewswire.com/news-release/2024/02/15/2829587/0/fr/Valneva-publie-son-chiffre-d-affaires-et-sa-tr%C3%A9sorerie-pour-l-exercice-2023-et-fournit-des-indications-pr%C3%A9liminaires-pour-l-exercice-2024.html"	"european_regulatory_news"	"2024-02-15 01:00:00"	"overnight"	1
"VALN"	"Valneva Reports Full Year 2023 Revenue and Cash,  Provides First 2024 Guidance"	"https://www.globenewswire.com/news-release/2024/02/15/2829587/0/en/Valneva-Reports-Full-Year-2023-Revenue-and-Cash-Provides-First-2024-Guidance.html"	"european_regulatory_news"	"2024-02-15 01:00:00"	"overnight"	1
"VALN"	"Valneva Reports Full Year 2023 Revenue and Cash,  Provides First 2024 Guidance"	"https://www.globenewswire.com/news-release/2024/02/15/2829587/0/en/Valneva-Reports-Full-Year-2023-Revenue-and-Cash-Provides-First-2024-Guidance.html"	"European Regulatory News"	"2024-02-15 01:00:00"	"overnight"	1
"VALN"	"Valneva publie son chiffre d’affaires et sa trésorerie pour l’exercice 2023 et fournit des indications préliminaires pour l’exercice 2024"	"https://www.globenewswire.com/news-release/2024/02/15/2829587/0/fr/Valneva-publie-son-chiffre-d-affaires-et-sa-tr%C3%A9sorerie-pour-l-exercice-2023-et-fournit-des-indications-pr%C3%A9liminaires-pour-l-exercice-2024.html"	"European Regulatory News"	"2024-02-15 01:00:00"	"overnight"	1
"ORIC"	"ORIC Pharmaceuticals to Participate in the Citi 2024 Virtual Oncology Leadership Summit"	"https://www.globenewswire.com/news-release/2024/02/14/2829482/0/en/ORIC-Pharmaceuticals-to-Participate-in-the-Citi-2024-Virtual-Oncology-Leadership-Summit.html"	"Calendar of Events"	"2024-02-14 16:30:00"	"after_hours"	16
"ORIC"	"ORIC Pharmaceuticals to Participate in the Citi 2024 Virtual Oncology Leadership Summit"	"https://www.globenewswire.com/news-release/2024/02/14/2829482/0/en/ORIC-Pharmaceuticals-to-Participate-in-the-Citi-2024-Virtual-Oncology-Leadership-Summit.html"	"calendar_of_events"	"2024-02-14 16:30:00"	"after_hours"	16
"ADPT"	"Adaptive Biotechnologies Reports Fourth Quarter and Full Year 2023 Financial Results"	"https://www.globenewswire.com/news-release/2024/02/14/2829461/0/en/Adaptive-Biotechnologies-Reports-Fourth-Quarter-and-Full-Year-2023-Financial-Results.html"	"conference_calls__webcasts"	"2024-02-14 16:05:00"	"after_hours"	16
"CELU"	"Celularity’s Tri-layer Decellularized, Dehydrated Human Amniotic Membrane Product Investigated as a Carrier of Induced Pluripotent Stem Cell Derived-Limbal Stem Cells in the Treatment of Severe Ocular Surface Disease"	"https://www.globenewswire.com/news-release/2024/02/14/2829457/0/en/Celularity-s-Tri-layer-Decellularized-Dehydrated-Human-Amniotic-Membrane-Product-Investigated-as-a-Carrier-of-Induced-Pluripotent-Stem-Cell-Derived-Limbal-Stem-Cells-in-the-Treatme.html"	"health"	"2024-02-14 16:05:00"	"after_hours"	16
"CELU"	"Celularity’s Tri-layer Decellularized, Dehydrated Human Amniotic Membrane Product Investigated as a Carrier of Induced Pluripotent Stem Cell Derived-Limbal Stem Cells in the Treatment of Severe Ocular Surface Disease"	"https://www.globenewswire.com/news-release/2024/02/14/2829457/0/en/Celularity-s-Tri-layer-Decellularized-Dehydrated-Human-Amniotic-Membrane-Product-Investigated-as-a-Carrier-of-Induced-Pluripotent-Stem-Cell-Derived-Limbal-Stem-Cells-in-the-Treatme.html"	"Health"	"2024-02-14 16:05:00"	"after_hours"	16
"ADPT"	"Adaptive Biotechnologies Reports Fourth Quarter and Full Year 2023 Financial Results"	"https://www.globenewswire.com/news-release/2024/02/14/2829461/0/en/Adaptive-Biotechnologies-Reports-Fourth-Quarter-and-Full-Year-2023-Financial-Results.html"	"Conference Calls/ Webcasts"	"2024-02-14 16:05:00"	"after_hours"	16
"GMAB"	"Genmab Files Annual Report with the U.S. Securities and Exchange Commission"	"https://www.globenewswire.com/news-release/2024/02/14/2829403/0/en/Genmab-Files-Annual-Report-with-the-U-S-Securities-and-Exchange-Commission.html"	"european_regulatory_news"	"2024-02-14 14:09:00"	"market_open"	14
"GMAB"	"Genmab Files Annual Report with the U.S. Securities and Exchange Commission"	"https://www.globenewswire.com/news-release/2024/02/14/2829403/0/en/Genmab-Files-Annual-Report-with-the-U-S-Securities-and-Exchange-Commission.html"	"European Regulatory News"	"2024-02-14 14:09:00"	"market_open"	14
"GMAB"	"Genmab Announces Initiation of Share Buy-Back Program"	"https://www.globenewswire.com/news-release/2024/02/14/2829305/0/en/Genmab-Announces-Initiation-of-Share-Buy-Back-Program.html"	"European Regulatory News"	"2024-02-14 11:41:00"	"market_open"	11
"GMAB"	"Genmab Announces Initiation of Share Buy-Back Program"	"https://www.globenewswire.com/news-release/2024/02/14/2829305/0/en/Genmab-Announces-Initiation-of-Share-Buy-Back-Program.html"	"european_regulatory_news"	"2024-02-14 11:41:00"	"market_open"	11
"GMAB"	"Genmab Publishes 2023 Annual Report"	"https://www.globenewswire.com/news-release/2024/02/14/2829266/0/en/Genmab-Publishes-2023-Annual-Report.html"	"European Regulatory News"	"2024-02-14 11:02:00"	"market_open"	11
"GMAB"	"Genmab Publishes 2023 Annual Report"	"https://www.globenewswire.com/news-release/2024/02/14/2829266/0/en/Genmab-Publishes-2023-Annual-Report.html"	"european_regulatory_news"	"2024-02-14 11:02:00"	"market_open"	11
"RENB"	"Statement of Renovaro Inc"	"https://www.globenewswire.com/news-release/2024/02/14/2829209/0/en/Statement-of-Renovaro-Inc.html"	"advisory"	"2024-02-14 10:01:00"	"market_open"	10
"RENB"	"Statement of Renovaro Inc"	"https://www.globenewswire.com/news-release/2024/02/14/2829209/0/en/Statement-of-Renovaro-Inc.html"	"Advisory"	"2024-02-14 10:01:00"	"market_open"	10
"YTEN"	"Yield10 Bioscience Grants Global License to VISION Bioenergy Oilseeds for Herbicide Tolerant Camelina Cultivated for the Production of Biofuel Feedstock"	"https://www.globenewswire.com/news-release/2024/02/14/2829136/34378/en/Yield10-Bioscience-Grants-Global-License-to-VISION-Bioenergy-Oilseeds-for-Herbicide-Tolerant-Camelina-Cultivated-for-the-Production-of-Biofuel-Feedstock.html"	"partnerships"	"2024-02-14 09:00:00"	"pre_market"	9
"YTEN"	"Yield10 Bioscience Grants Global License to VISION Bioenergy Oilseeds for Herbicide Tolerant Camelina Cultivated for the Production of Biofuel Feedstock"	"https://www.globenewswire.com/news-release/2024/02/14/2829136/34378/en/Yield10-Bioscience-Grants-Global-License-to-VISION-Bioenergy-Oilseeds-for-Herbicide-Tolerant-Camelina-Cultivated-for-the-Production-of-Biofuel-Feedstock.html"	"Partnerships"	"2024-02-14 09:00:00"	"pre_market"	9
"KA"	"Kineta to Present at Upcoming Investor Conferences"	"https://www.globenewswire.com/news-release/2024/02/14/2829081/0/en/Kineta-to-Present-at-Upcoming-Investor-Conferences.html"	"Calendar of Events"	"2024-02-14 08:30:00"	"pre_market"	8
"KA"	"Kineta to Present at Upcoming Investor Conferences"	"https://www.globenewswire.com/news-release/2024/02/14/2829081/0/en/Kineta-to-Present-at-Upcoming-Investor-Conferences.html"	"calendar_of_events"	"2024-02-14 08:30:00"	"pre_market"	8
"OCUP"	"Ocuphire Pharma Strengthens Leadership Team with Key Appointments"	"https://www.globenewswire.com/news-release/2024/02/14/2829026/0/en/Ocuphire-Pharma-Strengthens-Leadership-Team-with-Key-Appointments.html"	"Directors and Officers"	"2024-02-14 08:00:00"	"pre_market"	8
"INAB"	"IN8bio Announces Publication on Novel Gamma-Delta T Cell Therapy for Glioblastoma in Frontiers in Immunology"	"https://www.globenewswire.com/news-release/2024/02/14/2829025/0/en/IN8bio-Announces-Publication-on-Novel-Gamma-Delta-T-Cell-Therapy-for-Glioblastoma-in-Frontiers-in-Immunology.html"	"Clinical Study"	"2024-02-14 08:00:00"	"pre_market"	8
"INAB"	"IN8bio Announces Publication on Novel Gamma-Delta T Cell Therapy for Glioblastoma in Frontiers in Immunology"	"https://www.globenewswire.com/news-release/2024/02/14/2829025/0/en/IN8bio-Announces-Publication-on-Novel-Gamma-Delta-T-Cell-Therapy-for-Glioblastoma-in-Frontiers-in-Immunology.html"	"clinical_study"	"2024-02-14 08:00:00"	"pre_market"	8
"OCUP"	"Ocuphire Pharma Strengthens Leadership Team with Key Appointments"	"https://www.globenewswire.com/news-release/2024/02/14/2829026/0/en/Ocuphire-Pharma-Strengthens-Leadership-Team-with-Key-Appointments.html"	"directors_and_officers"	"2024-02-14 08:00:00"	"pre_market"	8
"OCGN"	"Ocugen to Host Clinical Showcase in New York City on Wednesday, February 21, 2024"	"https://www.globenewswire.com/news-release/2024/02/14/2829003/0/en/Ocugen-to-Host-Clinical-Showcase-in-New-York-City-on-Wednesday-February-21-2024.html"	"conference_calls__webcasts"	"2024-02-14 07:30:00"	"pre_market"	7
"NTLA"	"Intellia Therapeutics to Hold Conference Call to Discuss Fourth Quarter and Full-Year 2023 Earnings and Company Updates"	"https://www.globenewswire.com/news-release/2024/02/14/2828990/0/en/Intellia-Therapeutics-to-Hold-Conference-Call-to-Discuss-Fourth-Quarter-and-Full-Year-2023-Earnings-and-Company-Updates.html"	"calendar_of_events"	"2024-02-14 07:30:00"	"pre_market"	7
"ANVS"	"Annovis Bio Announces Last Patient Last Visit in the Phase II/III Study of Buntanetap in Alzheimer’s Disease"	"https://www.globenewswire.com/news-release/2024/02/14/2828993/0/en/Annovis-Bio-Announces-Last-Patient-Last-Visit-in-the-Phase-II-III-Study-of-Buntanetap-in-Alzheimer-s-Disease.html"	"clinical_study"	"2024-02-14 07:30:00"	"pre_market"	7
"OCGN"	"Ocugen to Host Clinical Showcase in New York City on Wednesday, February 21, 2024"	"https://www.globenewswire.com/news-release/2024/02/14/2829003/0/en/Ocugen-to-Host-Clinical-Showcase-in-New-York-City-on-Wednesday-February-21-2024.html"	"Conference Calls/ Webcasts"	"2024-02-14 07:30:00"	"pre_market"	7
"ANVS"	"Annovis Bio Announces Last Patient Last Visit in the Phase II/III Study of Buntanetap in Alzheimer’s Disease"	"https://www.globenewswire.com/news-release/2024/02/14/2828993/0/en/Annovis-Bio-Announces-Last-Patient-Last-Visit-in-the-Phase-II-III-Study-of-Buntanetap-in-Alzheimer-s-Disease.html"	"Clinical Study"	"2024-02-14 07:30:00"	"pre_market"	7
"NTLA"	"Intellia Therapeutics to Hold Conference Call to Discuss Fourth Quarter and Full-Year 2023 Earnings and Company Updates"	"https://www.globenewswire.com/news-release/2024/02/14/2828990/0/en/Intellia-Therapeutics-to-Hold-Conference-Call-to-Discuss-Fourth-Quarter-and-Full-Year-2023-Earnings-and-Company-Updates.html"	"Calendar of Events"	"2024-02-14 07:30:00"	"pre_market"	7
"TCRX"	"TScan Therapeutics to Host Virtual KOL Event to Discuss Updated Results from Phase 1 Heme Malignancies Study Presented at the 2024 Tandem Meetings of ASTCT and CIBMTR"	"https://www.globenewswire.com/news-release/2024/02/14/2828962/0/en/TScan-Therapeutics-to-Host-Virtual-KOL-Event-to-Discuss-Updated-Results-from-Phase-1-Heme-Malignancies-Study-Presented-at-the-2024-Tandem-Meetings-of-ASTCT-and-CIBMTR.html"	"calendar_of_events"	"2024-02-14 07:00:00"	"pre_market"	7
"PYPD"	"PolyPid Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results"	"https://www.globenewswire.com/news-release/2024/02/14/2828967/0/en/PolyPid-Provides-Corporate-Update-and-Reports-Fourth-Quarter-and-Full-Year-2023-Financial-Results.html"	"earnings_releases_and_operating_results"	"2024-02-14 07:00:00"	"pre_market"	7
"PYPD"	"PolyPid Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results"	"https://www.globenewswire.com/news-release/2024/02/14/2828967/0/en/PolyPid-Provides-Corporate-Update-and-Reports-Fourth-Quarter-and-Full-Year-2023-Financial-Results.html"	"Earnings Releases and Operating Results"	"2024-02-14 07:00:00"	"pre_market"	7
"TCRX"	"TScan Therapeutics to Host Virtual KOL Event to Discuss Updated Results from Phase 1 Heme Malignancies Study Presented at the 2024 Tandem Meetings of ASTCT and CIBMTR"	"https://www.globenewswire.com/news-release/2024/02/14/2828962/0/en/TScan-Therapeutics-to-Host-Virtual-KOL-Event-to-Discuss-Updated-Results-from-Phase-1-Heme-Malignancies-Study-Presented-at-the-2024-Tandem-Meetings-of-ASTCT-and-CIBMTR.html"	"Calendar of Events"	"2024-02-14 07:00:00"	"pre_market"	7
"SANN.SW"	"Santhera Announces Publication of Efficacy, Safety and Tolerability Data with Vamorolone (AGAMREE®) in Patients with Duchenne Muscular Dystrophy in Neurology"	"https://www.globenewswire.com/news-release/2024/02/14/2828764/0/en/Santhera-Announces-Publication-of-Efficacy-Safety-and-Tolerability-Data-with-Vamorolone-AGAMREE-in-Patients-with-Duchenne-Muscular-Dystrophy-in-Neurology.html"	"press_releases"	"2024-02-14 01:00:00"	"overnight"	1
"SANN.SW"	"Santhera gibt Veröffentlichung von Daten zur Wirksamkeit, Sicherheit und Verträglichkeit von Vamorolon (AGAMREE®) bei Patienten mit Duchenne-Muskeldystrophie in Neurology bekannt"	"https://www.globenewswire.com/news-release/2024/02/14/2828764/0/de/Santhera-gibt-Ver%C3%B6ffentlichung-von-Daten-zur-Wirksamkeit-Sicherheit-und-Vertr%C3%A4glichkeit-von-Vamorolon-AGAMREE-bei-Patienten-mit-Duchenne-Muskeldystrophie-in-Neurology-bekannt.html"	"press_releases"	"2024-02-14 01:00:00"	"overnight"	1
"SANN.SW"	"Santhera gibt Veröffentlichung von Daten zur Wirksamkeit, Sicherheit und Verträglichkeit von Vamorolon (AGAMREE®) bei Patienten mit Duchenne-Muskeldystrophie in Neurology bekannt"	"https://www.globenewswire.com/news-release/2024/02/14/2828764/0/de/Santhera-gibt-Ver%C3%B6ffentlichung-von-Daten-zur-Wirksamkeit-Sicherheit-und-Vertr%C3%A4glichkeit-von-Vamorolon-AGAMREE-bei-Patienten-mit-Duchenne-Muskeldystrophie-in-Neurology-bekannt.html"	"Press releases"	"2024-02-14 01:00:00"	"overnight"	1
"SANN.SW"	"Santhera Announces Publication of Efficacy, Safety and Tolerability Data with Vamorolone (AGAMREE®) in Patients with Duchenne Muscular Dystrophy in Neurology"	"https://www.globenewswire.com/news-release/2024/02/14/2828764/0/en/Santhera-Announces-Publication-of-Efficacy-Safety-and-Tolerability-Data-with-Vamorolone-AGAMREE-in-Patients-with-Duchenne-Muscular-Dystrophy-in-Neurology.html"	"Press releases"	"2024-02-14 01:00:00"	"overnight"	1
"PCIB.OL"	"PCI Biotech second half 2023 interim results"	"https://www.globenewswire.com/news-release/2024/02/14/2828767/0/en/PCI-Biotech-second-half-2023-interim-results.html"	"european_regulatory_news"	"2024-02-14 01:00:00"	"overnight"	1
"PCIB.OL"	"PCI Biotech second half 2023 interim results"	"https://www.globenewswire.com/news-release/2024/02/14/2828767/0/en/PCI-Biotech-second-half-2023-interim-results.html"	"European Regulatory News"	"2024-02-14 01:00:00"	"overnight"	1
"NANO.PA"	"Voting Rights and Shares Capital of the Company"	"https://www.globenewswire.com/news-release/2024/02/13/2828661/0/en/Voting-Rights-and-Shares-Capital-of-the-Company.html"	"European Regulatory News"	"2024-02-13 16:15:00"	"after_hours"	16
"NANO.PA"	"Voting Rights and Shares Capital of the Company"	"https://www.globenewswire.com/news-release/2024/02/13/2828661/0/en/Voting-Rights-and-Shares-Capital-of-the-Company.html"	"european_regulatory_news"	"2024-02-13 16:15:00"	"after_hours"	16
"NANO.PA"	"INFORMATION MENSUELLE RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS COMPOSANT LE CAPITAL SOCIAL"	"https://www.globenewswire.com/news-release/2024/02/13/2828661/0/fr/INFORMATION-MENSUELLE-RELATIVE-AU-NOMBRE-TOTAL-DE-DROITS-DE-VOTE-ET-D-ACTIONS-COMPOSANT-LE-CAPITAL-SOCIAL.html"	"european_regulatory_news"	"2024-02-13 16:15:00"	"after_hours"	16
"NANO.PA"	"INFORMATION MENSUELLE RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS COMPOSANT LE CAPITAL SOCIAL"	"https://www.globenewswire.com/news-release/2024/02/13/2828661/0/fr/INFORMATION-MENSUELLE-RELATIVE-AU-NOMBRE-TOTAL-DE-DROITS-DE-VOTE-ET-D-ACTIONS-COMPOSANT-LE-CAPITAL-SOCIAL.html"	"European Regulatory News"	"2024-02-13 16:15:00"	"after_hours"	16
"RZLT"	"Rezolute Reports Second Quarter Fiscal 2024 Results and Provides Business Update"	"https://www.globenewswire.com/news-release/2024/02/13/2828647/0/en/Rezolute-Reports-Second-Quarter-Fiscal-2024-Results-and-Provides-Business-Update.html"	"Earnings Releases and Operating Results"	"2024-02-13 16:05:00"	"after_hours"	16
"RZLT"	"Rezolute Reports Second Quarter Fiscal 2024 Results and Provides Business Update"	"https://www.globenewswire.com/news-release/2024/02/13/2828647/0/en/Rezolute-Reports-Second-Quarter-Fiscal-2024-Results-and-Provides-Business-Update.html"	"earnings_releases_and_operating_results"	"2024-02-13 16:05:00"	"after_hours"	16
"RENB"	"Cutting Edge AI Company GEDiCube and Cyclomics sign binding LOI to join forces and position themselves at the forefront of the global liquid biopsy marketplace"	"https://www.globenewswire.com/news-release/2024/02/13/2828380/0/en/Cutting-Edge-AI-Company-GEDiCube-and-Cyclomics-sign-binding-LOI-to-join-forces-and-position-themselves-at-the-forefront-of-the-global-liquid-biopsy-marketplace.html"	"Mergers and Acquisitions"	"2024-02-13 09:46:00"	"market_open"	9
"RENB"	"Cutting Edge AI Company GEDiCube and Cyclomics sign binding LOI to join forces and position themselves at the forefront of the global liquid biopsy marketplace"	"https://www.globenewswire.com/news-release/2024/02/13/2828380/0/en/Cutting-Edge-AI-Company-GEDiCube-and-Cyclomics-sign-binding-LOI-to-join-forces-and-position-themselves-at-the-forefront-of-the-global-liquid-biopsy-marketplace.html"	"mergers_and_acquisitions"	"2024-02-13 09:46:00"	"market_open"	9
"RENB"	"AI Pioneer GEDi Cube and Biotech Innovator Renovaro Biosciences Combine Forces to Accelerate Personalized Medicine"	"https://www.globenewswire.com/news-release/2024/02/13/2828372/0/en/AI-Pioneer-GEDi-Cube-and-Biotech-Innovator-Renovaro-Biosciences-Combine-Forces-to-Accelerate-Personalized-Medicine.html"	"mergers_and_acquisitions"	"2024-02-13 09:31:00"	"market_open"	9
"RENB"	"AI Pioneer GEDi Cube and Biotech Innovator Renovaro Biosciences Combine Forces to Accelerate Personalized Medicine"	"https://www.globenewswire.com/news-release/2024/02/13/2828372/0/en/AI-Pioneer-GEDi-Cube-and-Biotech-Innovator-Renovaro-Biosciences-Combine-Forces-to-Accelerate-Personalized-Medicine.html"	"Mergers and Acquisitions"	"2024-02-13 09:31:00"	"market_open"	9
"BTAI"	"BioXcel Therapeutics Announces Termination of Proposed Public Offering"	"https://www.globenewswire.com/news-release/2024/02/13/2828330/0/en/BioXcel-Therapeutics-Announces-Termination-of-Proposed-Public-Offering.html"	"financing_agreements"	"2024-02-13 09:00:00"	"pre_market"	9
"BTAI"	"BioXcel Therapeutics Announces Termination of Proposed Public Offering"	"https://www.globenewswire.com/news-release/2024/02/13/2828330/0/en/BioXcel-Therapeutics-Announces-Termination-of-Proposed-Public-Offering.html"	"Financing Agreements"	"2024-02-13 09:00:00"	"pre_market"	9
"CRSP"	"CRISPR Therapeutics Announces $280 Million Registered Direct Offering"	"https://www.globenewswire.com/news-release/2024/02/13/2828258/0/en/CRISPR-Therapeutics-Announces-280-Million-Registered-Direct-Offering.html"	"Changes in company's own shares"	"2024-02-13 08:30:00"	"pre_market"	8
"DYAI"	"Dyadic and Cygnus Technologies Announce Partnership To Provide C1 HCP ELISA Assay to Enhance Quality Assurance in Biomanufacturing"	"https://www.globenewswire.com/news-release/2024/02/13/2828243/0/en/Dyadic-and-Cygnus-Technologies-Announce-Partnership-To-Provide-C1-HCP-ELISA-Assay-to-Enhance-Quality-Assurance-in-Biomanufacturing.html"	"Partnerships"	"2024-02-13 08:30:00"	"pre_market"	8
"CRSP"	"CRISPR Therapeutics Announces $280 Million Registered Direct Offering"	"https://www.globenewswire.com/news-release/2024/02/13/2828258/0/en/CRISPR-Therapeutics-Announces-280-Million-Registered-Direct-Offering.html"	"changes_in_company's_own_shares"	"2024-02-13 08:30:00"	"pre_market"	8
"DYAI"	"Dyadic and Cygnus Technologies Announce Partnership To Provide C1 HCP ELISA Assay to Enhance Quality Assurance in Biomanufacturing"	"https://www.globenewswire.com/news-release/2024/02/13/2828243/0/en/Dyadic-and-Cygnus-Technologies-Announce-Partnership-To-Provide-C1-HCP-ELISA-Assay-to-Enhance-Quality-Assurance-in-Biomanufacturing.html"	"partnerships"	"2024-02-13 08:30:00"	"pre_market"	8
"RAPT"	"RAPT Therapeutics Bolsters Leadership Team with the Appointment of Nipun Davar, Ph.D., as Senior Vice President of Technical Operations"	"https://www.globenewswire.com/news-release/2024/02/13/2828209/0/en/RAPT-Therapeutics-Bolsters-Leadership-Team-with-the-Appointment-of-Nipun-Davar-Ph-D-as-Senior-Vice-President-of-Technical-Operations.html"	"product___services_announcement"	"2024-02-13 08:00:00"	"pre_market"	8
"RAPT"	"RAPT Therapeutics Bolsters Leadership Team with the Appointment of Nipun Davar, Ph.D., as Senior Vice President of Technical Operations"	"https://www.globenewswire.com/news-release/2024/02/13/2828209/0/en/RAPT-Therapeutics-Bolsters-Leadership-Team-with-the-Appointment-of-Nipun-Davar-Ph-D-as-Senior-Vice-President-of-Technical-Operations.html"	"Product / Services Announcement"	"2024-02-13 08:00:00"	"pre_market"	8
"CADL"	"CAN-3110 Receives FDA Fast Track Designation for Treatment of Recurrent High-Grade Glioma"	"https://www.globenewswire.com/news-release/2024/02/13/2828140/0/en/CAN-3110-Receives-FDA-Fast-Track-Designation-for-Treatment-of-Recurrent-High-Grade-Glioma.html"	"health"	"2024-02-13 07:30:00"	"pre_market"	7
"CADL"	"CAN-3110 Receives FDA Fast Track Designation for Treatment of Recurrent High-Grade Glioma"	"https://www.globenewswire.com/news-release/2024/02/13/2828140/0/en/CAN-3110-Receives-FDA-Fast-Track-Designation-for-Treatment-of-Recurrent-High-Grade-Glioma.html"	"Health"	"2024-02-13 07:30:00"	"pre_market"	7
"KBLB"	"Kraig Biocraft Laboratories Announces New Spider Silk Production Facility in Vietnam's Silk Capital"	"https://www.globenewswire.com/news-release/2024/02/13/2828120/0/en/Kraig-Biocraft-Laboratories-Announces-New-Spider-Silk-Production-Facility-in-Vietnam-s-Silk-Capital.html"	"Product / Services Announcement"	"2024-02-13 07:05:00"	"pre_market"	7
"KBLB"	"Kraig Biocraft Laboratories Announces New Spider Silk Production Facility in Vietnam's Silk Capital"	"https://www.globenewswire.com/news-release/2024/02/13/2828120/0/en/Kraig-Biocraft-Laboratories-Announces-New-Spider-Silk-Production-Facility-in-Vietnam-s-Silk-Capital.html"	"product___services_announcement"	"2024-02-13 07:05:00"	"pre_market"	7
"EYEN"	"Eyenovia Announces FDA Approval of Redwood City as Commercial Manufacturing Facility"	"https://www.globenewswire.com/news-release/2024/02/13/2828089/0/en/Eyenovia-Announces-FDA-Approval-of-Redwood-City-as-Commercial-Manufacturing-Facility.html"	"Product / Services Announcement"	"2024-02-13 07:00:00"	"pre_market"	7
"EYEN"	"Eyenovia Announces FDA Approval of Redwood City as Commercial Manufacturing Facility"	"https://www.globenewswire.com/news-release/2024/02/13/2828089/0/en/Eyenovia-Announces-FDA-Approval-of-Redwood-City-as-Commercial-Manufacturing-Facility.html"	"product___services_announcement"	"2024-02-13 07:00:00"	"pre_market"	7
"STTK"	"Shattuck Labs Enters into Strategic Collaboration and License Agreement with Ono Pharmaceutical to Generate Bifunctional Fusion Proteins for the Treatment of Autoimmune and Inflammatory Diseases"	"https://www.globenewswire.com/news-release/2024/02/13/2828053/0/en/Shattuck-Labs-Enters-into-Strategic-Collaboration-and-License-Agreement-with-Ono-Pharmaceutical-to-Generate-Bifunctional-Fusion-Proteins-for-the-Treatment-of-Autoimmune-and-Inflamm.html"	"Licensing Agreements"	"2024-02-13 06:00:00"	"pre_market"	6
"STTK"	"Shattuck Labs Enters into Strategic Collaboration and License Agreement with Ono Pharmaceutical to Generate Bifunctional Fusion Proteins for the Treatment of Autoimmune and Inflammatory Diseases"	"https://www.globenewswire.com/news-release/2024/02/13/2828053/0/en/Shattuck-Labs-Enters-into-Strategic-Collaboration-and-License-Agreement-with-Ono-Pharmaceutical-to-Generate-Bifunctional-Fusion-Proteins-for-the-Treatment-of-Autoimmune-and-Inflamm.html"	"licensing_agreements"	"2024-02-13 06:00:00"	"pre_market"	6
"CRSP"	"European Commission Approves First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™ (exagamglogene autotemcel), for the Treatment of Sickle Cell Disease (SCD) and Transfusion-Dependent Beta Thalassemia (TDT)"	"https://www.globenewswire.com/news-release/2024/02/13/2827965/0/en/European-Commission-Approves-First-CRISPR-Cas9-Gene-Edited-Therapy-CASGEVY-exagamglogene-autotemcel-for-the-Treatment-of-Sickle-Cell-Disease-SCD-and-Transfusion-Dependent-Beta-Thal.html"	"Clinical Study"	"2024-02-13 02:30:00"	"overnight"	2
"CRSP"	"European Commission Approves First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™ (exagamglogene autotemcel), for the Treatment of Sickle Cell Disease (SCD) and Transfusion-Dependent Beta Thalassemia (TDT)"	"https://www.globenewswire.com/news-release/2024/02/13/2827965/0/en/European-Commission-Approves-First-CRISPR-Cas9-Gene-Edited-Therapy-CASGEVY-exagamglogene-autotemcel-for-the-Treatment-of-Sickle-Cell-Disease-SCD-and-Transfusion-Dependent-Beta-Thal.html"	"clinical_study"	"2024-02-13 02:30:00"	"overnight"	2
"BIIB"	"Biogen Received European Commission Approval for SKYCLARYS® (omaveloxolone), the First Therapy to Treat Friedreich’s Ataxia"	"https://www.globenewswire.com/news-release/2024/02/12/2827864/0/en/Biogen-Received-European-Commission-Approval-for-SKYCLARYS-omaveloxolone-the-First-Therapy-to-Treat-Friedreich-s-Ataxia.html"	"product___services_announcement"	"2024-02-12 16:06:00"	"after_hours"	16
"BIIB"	"Biogen Received European Commission Approval for SKYCLARYS® (omaveloxolone), the First Therapy to Treat Friedreich’s Ataxia"	"https://www.globenewswire.com/news-release/2024/02/12/2827864/0/en/Biogen-Received-European-Commission-Approval-for-SKYCLARYS-omaveloxolone-the-First-Therapy-to-Treat-Friedreich-s-Ataxia.html"	"Product / Services Announcement"	"2024-02-12 16:06:00"	"after_hours"	16
"GTHX"	"G1 Therapeutics to Continue Pivotal Phase 3 Trial of Trilaciclib in Metastatic Triple Negative Breast Cancer Following Interim Analysis by Independent Data Monitoring Committee"	"https://www.globenewswire.com/news-release/2024/02/12/2827863/0/en/G1-Therapeutics-to-Continue-Pivotal-Phase-3-Trial-of-Trilaciclib-in-Metastatic-Triple-Negative-Breast-Cancer-Following-Interim-Analysis-by-Independent-Data-Monitoring-Committee.html"	"clinical_study"	"2024-02-12 16:05:00"	"after_hours"	16
"GTHX"	"G1 Therapeutics to Continue Pivotal Phase 3 Trial of Trilaciclib in Metastatic Triple Negative Breast Cancer Following Interim Analysis by Independent Data Monitoring Committee"	"https://www.globenewswire.com/news-release/2024/02/12/2827863/0/en/G1-Therapeutics-to-Continue-Pivotal-Phase-3-Trial-of-Trilaciclib-in-Metastatic-Triple-Negative-Breast-Cancer-Following-Interim-Analysis-by-Independent-Data-Monitoring-Committee.html"	"Clinical Study"	"2024-02-12 16:05:00"	"after_hours"	16
"TTOO"	"T2 Biosystems Receives FDA 510(k) Clearance for the Expanded T2Bacteria Panel"	"https://www.globenewswire.com/news-release/2024/02/12/2827565/32489/en/T2-Biosystems-Receives-FDA-510-k-Clearance-for-the-Expanded-T2Bacteria-Panel.html"	"Product / Services Announcement"	"2024-02-12 09:00:00"	"pre_market"	9
"INMB"	"INmune Bio to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference"	"https://www.globenewswire.com/news-release/2024/02/12/2827562/0/en/INmune-Bio-to-Participate-in-the-Oppenheimer-34th-Annual-Healthcare-Life-Sciences-Conference.html"	"Conference Calls/ Webcasts"	"2024-02-12 09:00:00"	"pre_market"	9
"INMB"	"INmune Bio to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference"	"https://www.globenewswire.com/news-release/2024/02/12/2827562/0/en/INmune-Bio-to-Participate-in-the-Oppenheimer-34th-Annual-Healthcare-Life-Sciences-Conference.html"	"conference_calls__webcasts"	"2024-02-12 09:00:00"	"pre_market"	9
"TTOO"	"T2 Biosystems Receives FDA 510(k) Clearance for the Expanded T2Bacteria Panel"	"https://www.globenewswire.com/news-release/2024/02/12/2827565/32489/en/T2-Biosystems-Receives-FDA-510-k-Clearance-for-the-Expanded-T2Bacteria-Panel.html"	"product___services_announcement"	"2024-02-12 09:00:00"	"pre_market"	9
"CDTX"	"Cidara Therapeutics Receives $11.14 Million Milestone Payment Following European Approval of REZZAYO"	"https://www.globenewswire.com/news-release/2024/02/12/2827490/0/en/Cidara-Therapeutics-Receives-11-14-Million-Milestone-Payment-Following-European-Approval-of-REZZAYO.html"	"health"	"2024-02-12 08:00:00"	"pre_market"	8
"MDAI"	"Spectral AI Appoints Dr. J. Michael DiMaio to Board of Directors"	"https://www.globenewswire.com/news-release/2024/02/12/2827481/0/en/Spectral-AI-Appoints-Dr-J-Michael-DiMaio-to-Board-of-Directors.html"	"Directors and Officers"	"2024-02-12 08:00:00"	"pre_market"	8
"MDG1.DE"	"Medigene Announces Indication Selection  for the Clinical Development of its Lead 3rd Generation TCR-T Therapy Program in Solid Tumors"	"https://www.globenewswire.com/news-release/2024/02/12/2827472/0/en/Medigene-Announces-Indication-Selection-for-the-Clinical-Development-of-its-Lead-3rd-Generation-TCR-T-Therapy-Program-in-Solid-Tumors.html"	"Company Announcement"	"2024-02-12 08:00:00"	"pre_market"	8
"MDAI"	"Spectral AI Appoints Dr. J. Michael DiMaio to Board of Directors"	"https://www.globenewswire.com/news-release/2024/02/12/2827481/0/en/Spectral-AI-Appoints-Dr-J-Michael-DiMaio-to-Board-of-Directors.html"	"directors_and_officers"	"2024-02-12 08:00:00"	"pre_market"	8
"MDG1.DE"	"Medigene Announces Indication Selection  for the Clinical Development of its Lead 3rd Generation TCR-T Therapy Program in Solid Tumors"	"https://www.globenewswire.com/news-release/2024/02/12/2827472/0/en/Medigene-Announces-Indication-Selection-for-the-Clinical-Development-of-its-Lead-3rd-Generation-TCR-T-Therapy-Program-in-Solid-Tumors.html"	"company_announcement"	"2024-02-12 08:00:00"	"pre_market"	8
"CDTX"	"Cidara Therapeutics Receives $11.14 Million Milestone Payment Following European Approval of REZZAYO"	"https://www.globenewswire.com/news-release/2024/02/12/2827490/0/en/Cidara-Therapeutics-Receives-11-14-Million-Milestone-Payment-Following-European-Approval-of-REZZAYO.html"	"Health"	"2024-02-12 08:00:00"	"pre_market"	8
"BTAI"	"BioXcel Therapeutics Receives FDA Fast Track Designation for BXCL701 for Treatment of Small Cell Neuroendocrine Prostate Cancer (SCNC)"	"https://www.globenewswire.com/news-release/2024/02/12/2827423/0/en/BioXcel-Therapeutics-Receives-FDA-Fast-Track-Designation-for-BXCL701-for-Treatment-of-Small-Cell-Neuroendocrine-Prostate-Cancer-SCNC.html"	"health"	"2024-02-12 07:14:00"	"pre_market"	7
"BTAI"	"BioXcel Therapeutics Receives FDA Fast Track Designation for BXCL701 for Treatment of Small Cell Neuroendocrine Prostate Cancer (SCNC)"	"https://www.globenewswire.com/news-release/2024/02/12/2827423/0/en/BioXcel-Therapeutics-Receives-FDA-Fast-Track-Designation-for-BXCL701-for-Treatment-of-Small-Cell-Neuroendocrine-Prostate-Cancer-SCNC.html"	"Health"	"2024-02-12 07:14:00"	"pre_market"	7
"PYPD"	"PolyPid Announces Enrollment of the 100th Patient in the Ongoing SHIELD II Phase 3 Trial"	"https://www.globenewswire.com/news-release/2024/02/12/2827386/0/en/PolyPid-Announces-Enrollment-of-the-100th-Patient-in-the-Ongoing-SHIELD-II-Phase-3-Trial.html"	"clinical_study"	"2024-02-12 07:00:00"	"pre_market"	7
"PYPD"	"PolyPid Announces Enrollment of the 100th Patient in the Ongoing SHIELD II Phase 3 Trial"	"https://www.globenewswire.com/news-release/2024/02/12/2827386/0/en/PolyPid-Announces-Enrollment-of-the-100th-Patient-in-the-Ongoing-SHIELD-II-Phase-3-Trial.html"	"Clinical Study"	"2024-02-12 07:00:00"	"pre_market"	7
"NSPR"	"InspireMD Appoints Principal Investigators for C-GUARDIANS II Clinical Trial of the SwitchGuard™ Neuroprotection System"	"https://www.globenewswire.com/news-release/2024/02/12/2827400/0/en/InspireMD-Appoints-Principal-Investigators-for-C-GUARDIANS-II-Clinical-Trial-of-the-SwitchGuard-Neuroprotection-System.html"	"clinical_study"	"2024-02-12 07:00:00"	"pre_market"	7
"MDWD"	"MediWound Announces Positive Results in Head-to-Head Comparison of EscharEx® vs. SANTYL® within the ChronEx Phase II Randomized Controlled Study"	"https://www.globenewswire.com/news-release/2024/02/12/2827407/30505/en/MediWound-Announces-Positive-Results-in-Head-to-Head-Comparison-of-EscharEx-vs-SANTYL-within-the-ChronEx-Phase-II-Randomized-Controlled-Study.html"	"Health"	"2024-02-12 07:00:00"	"pre_market"	7
"NSPR"	"InspireMD Appoints Principal Investigators for C-GUARDIANS II Clinical Trial of the SwitchGuard™ Neuroprotection System"	"https://www.globenewswire.com/news-release/2024/02/12/2827400/0/en/InspireMD-Appoints-Principal-Investigators-for-C-GUARDIANS-II-Clinical-Trial-of-the-SwitchGuard-Neuroprotection-System.html"	"Clinical Study"	"2024-02-12 07:00:00"	"pre_market"	7
"MDWD"	"MediWound Announces Positive Results in Head-to-Head Comparison of EscharEx® vs. SANTYL® within the ChronEx Phase II Randomized Controlled Study"	"https://www.globenewswire.com/news-release/2024/02/12/2827407/30505/en/MediWound-Announces-Positive-Results-in-Head-to-Head-Comparison-of-EscharEx-vs-SANTYL-within-the-ChronEx-Phase-II-Randomized-Controlled-Study.html"	"health"	"2024-02-12 07:00:00"	"pre_market"	7
"PCIB.OL"	"PCI Biotech: Invitation to second half interim 2023 results presentation"	"https://www.globenewswire.com/news-release/2024/02/12/2827225/0/en/PCI-Biotech-Invitation-to-second-half-interim-2023-results-presentation.html"	"european_regulatory_news"	"2024-02-12 03:26:00"	"overnight"	3
"PCIB.OL"	"PCI Biotech: Invitation to second half interim 2023 results presentation"	"https://www.globenewswire.com/news-release/2024/02/12/2827225/0/en/PCI-Biotech-Invitation-to-second-half-interim-2023-results-presentation.html"	"European Regulatory News"	"2024-02-12 03:26:00"	"overnight"	3
"ADAG"	"Adagene Announces Progress and Expansion of Clinical Collaboration Program for Masked, Anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with KEYTRUDA® (pembrolizumab) to Demonstrate Further Efficacy in Patients with Metastatic Microsatellite-stable (MSS) Colorectal Cancer (CRC)"	"https://www.globenewswire.com/news-release/2024/02/09/2826677/0/en/Adagene-Announces-Progress-and-Expansion-of-Clinical-Collaboration-Program-for-Masked-Anti-CTLA-4-SAFEbody-ADG126-muzastotug-in-Combination-with-KEYTRUDA-pembrolizumab-to-Demonstra.html"	"Product / Services Announcement"	"2024-02-09 06:00:00"	"pre_market"	6
"ADAG"	"Adagene Announces Progress and Expansion of Clinical Collaboration Program for Masked, Anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with KEYTRUDA® (pembrolizumab) to Demonstrate Further Efficacy in Patients with Metastatic Microsatellite-stable (MSS) Colorectal Cancer (CRC)"	"https://www.globenewswire.com/news-release/2024/02/09/2826677/0/en/Adagene-Announces-Progress-and-Expansion-of-Clinical-Collaboration-Program-for-Masked-Anti-CTLA-4-SAFEbody-ADG126-muzastotug-in-Combination-with-KEYTRUDA-pembrolizumab-to-Demonstra.html"	"product___services_announcement"	"2024-02-09 06:00:00"	"pre_market"	6
"NZYM-B.CO"	"Invitation to an extraordinary shareholders’ meeting of Novozymes A/S"	"https://www.globenewswire.com/news-release/2024/02/09/2826627/0/en/Invitation-to-an-extraordinary-shareholders-meeting-of-Novozymes-A-S.html"	"European Regulatory News"	"2024-02-09 04:00:00"	"pre_market"	4
"NZYM-B.CO"	"Invitation to an extraordinary shareholders’ meeting of Novozymes A/S"	"https://www.globenewswire.com/news-release/2024/02/09/2826627/0/en/Invitation-to-an-extraordinary-shareholders-meeting-of-Novozymes-A-S.html"	"european_regulatory_news"	"2024-02-09 04:00:00"	"pre_market"	4
"ORPHA.CO"	"US Security Class action forlig afsluttet"	"https://www.globenewswire.com/news-release/2024/02/09/2826601/0/da/US-Security-Class-action-forlig-afsluttet.html"	"European Regulatory News"	"2024-02-09 02:34:00"	"overnight"	2
"ORPHA.CO"	"US Security Class action forlig afsluttet"	"https://www.globenewswire.com/news-release/2024/02/09/2826601/0/da/US-Security-Class-action-forlig-afsluttet.html"	"european_regulatory_news"	"2024-02-09 02:34:00"	"overnight"	2
"IMMX"	"Immix Biopharma Announces Closing of $15 Million Public Offering of Common Stock"	"https://www.globenewswire.com/news-release/2024/02/08/2826486/0/en/Immix-Biopharma-Announces-Closing-of-15-Million-Public-Offering-of-Common-Stock.html"	"Initial Public Offerings"	"2024-02-08 16:45:00"	"after_hours"	16
"IMMX"	"Immix Biopharma Announces Closing of $15 Million Public Offering of Common Stock"	"https://www.globenewswire.com/news-release/2024/02/08/2826486/0/en/Immix-Biopharma-Announces-Closing-of-15-Million-Public-Offering-of-Common-Stock.html"	"initial_public_offerings"	"2024-02-08 16:45:00"	"after_hours"	16
"AKYA"	"Akoya to Report Fourth Quarter and Full Year 2023 Financial Results on March 4th, 2024 and Participate at an Upcoming Investor Conference"	"https://www.globenewswire.com/news-release/2024/02/08/2826431/0/en/Akoya-to-Report-Fourth-Quarter-and-Full-Year-2023-Financial-Results-on-March-4th-2024-and-Participate-at-an-Upcoming-Investor-Conference.html"	"conference_calls__webcasts"	"2024-02-08 16:05:00"	"after_hours"	16
"AKYA"	"Akoya to Report Fourth Quarter and Full Year 2023 Financial Results on March 4th, 2024 and Participate at an Upcoming Investor Conference"	"https://www.globenewswire.com/news-release/2024/02/08/2826431/0/en/Akoya-to-Report-Fourth-Quarter-and-Full-Year-2023-Financial-Results-on-March-4th-2024-and-Participate-at-an-Upcoming-Investor-Conference.html"	"Conference Calls/ Webcasts"	"2024-02-08 16:05:00"	"after_hours"	16
"BTAI"	"BioXcel Therapeutics Announces Proposed Public Offering"	"https://www.globenewswire.com/news-release/2024/02/08/2826423/0/en/BioXcel-Therapeutics-Announces-Proposed-Public-Offering.html"	"initial_public_offerings"	"2024-02-08 16:01:00"	"after_hours"	16
"BTAI"	"BioXcel Therapeutics Announces Proposed Public Offering"	"https://www.globenewswire.com/news-release/2024/02/08/2826423/0/en/BioXcel-Therapeutics-Announces-Proposed-Public-Offering.html"	"Initial Public Offerings"	"2024-02-08 16:01:00"	"after_hours"	16
"NZYM-B.CO"	"The Novozymes Report 2023"	"https://www.globenewswire.com/news-release/2024/02/08/2826390/0/en/The-Novozymes-Report-2023.html"	"european_regulatory_news"	"2024-02-08 13:52:00"	"market_open"	13
"NZYM-B.CO"	"The Novozymes Report 2023"	"https://www.globenewswire.com/news-release/2024/02/08/2826390/0/en/The-Novozymes-Report-2023.html"	"European Regulatory News"	"2024-02-08 13:52:00"	"market_open"	13
"BICX"	"BioCorRx Pharmaceuticals Inc. Appoints Neuroscientist Dr. Kate DeVarney to the Board of Directors"	"https://www.globenewswire.com/news-release/2024/02/08/2826159/0/en/BioCorRx-Pharmaceuticals-Inc-Appoints-Neuroscientist-Dr-Kate-DeVarney-to-the-Board-of-Directors.html"	"Directors and Officers"	"2024-02-08 09:52:00"	"market_open"	9
"BICX"	"BioCorRx Pharmaceuticals Inc. Appoints Neuroscientist Dr. Kate DeVarney to the Board of Directors"	"https://www.globenewswire.com/news-release/2024/02/08/2826159/0/en/BioCorRx-Pharmaceuticals-Inc-Appoints-Neuroscientist-Dr-Kate-DeVarney-to-the-Board-of-Directors.html"	"directors_and_officers"	"2024-02-08 09:52:00"	"market_open"	9
"MLYS"	"Mineralys Therapeutics Announces $120 Million Private Placement Financing"	"https://www.globenewswire.com/news-release/2024/02/08/2825968/0/en/Mineralys-Therapeutics-Announces-120-Million-Private-Placement-Financing.html"	"financing_agreements"	"2024-02-08 08:00:00"	"pre_market"	8
"BIOR"	"Biora Therapeutics Announces Participation in Canaccord Genuity Inflammatory Bowel Disease Symposium"	"https://www.globenewswire.com/news-release/2024/02/08/2825975/0/en/Biora-Therapeutics-Announces-Participation-in-Canaccord-Genuity-Inflammatory-Bowel-Disease-Symposium.html"	"Calendar of Events"	"2024-02-08 08:00:00"	"pre_market"	8
"MLYS"	"Mineralys Therapeutics Announces $120 Million Private Placement Financing"	"https://www.globenewswire.com/news-release/2024/02/08/2825968/0/en/Mineralys-Therapeutics-Announces-120-Million-Private-Placement-Financing.html"	"Financing Agreements"	"2024-02-08 08:00:00"	"pre_market"	8
"BIOR"	"Biora Therapeutics Announces Participation in Canaccord Genuity Inflammatory Bowel Disease Symposium"	"https://www.globenewswire.com/news-release/2024/02/08/2825975/0/en/Biora-Therapeutics-Announces-Participation-in-Canaccord-Genuity-Inflammatory-Bowel-Disease-Symposium.html"	"calendar_of_events"	"2024-02-08 08:00:00"	"pre_market"	8
"BCDA"	"BioCardia Announces Activation of CardiAMP Heart Failure II Phase 3 Pivotal Study Recently Approved by FDA"	"https://www.globenewswire.com/news-release/2024/02/08/2825876/0/en/BioCardia-Announces-Activation-of-CardiAMP-Heart-Failure-II-Phase-3-Pivotal-Study-Recently-Approved-by-FDA.html"	"Clinical Study"	"2024-02-08 07:00:00"	"pre_market"	7
"BCDA"	"BioCardia Announces Activation of CardiAMP Heart Failure II Phase 3 Pivotal Study Recently Approved by FDA"	"https://www.globenewswire.com/news-release/2024/02/08/2825876/0/en/BioCardia-Announces-Activation-of-CardiAMP-Heart-Failure-II-Phase-3-Pivotal-Study-Recently-Approved-by-FDA.html"	"clinical_study"	"2024-02-08 07:00:00"	"pre_market"	7
"EVAX"	"Evaxion erfüllt wieder die Anforderungen der Nasdaq an den Mindestangebotspreis"	"https://www.globenewswire.com/news-release/2024/02/08/2825836/0/de/Evaxion-erf%C3%BCllt-wieder-die-Anforderungen-der-Nasdaq-an-den-Mindestangebotspreis.html"	"Financing Agreements"	"2024-02-08 06:20:00"	"pre_market"	6
"EVAX"	"Evaxion erfüllt wieder die Anforderungen der Nasdaq an den Mindestangebotspreis"	"https://www.globenewswire.com/news-release/2024/02/08/2825836/0/de/Evaxion-erf%C3%BCllt-wieder-die-Anforderungen-der-Nasdaq-an-den-Mindestangebotspreis.html"	"financing_agreements"	"2024-02-08 06:20:00"	"pre_market"	6
"EVAX"	"Evaxion répond de nouveau aux exigences du Nasdaq en matière de prix minimum de l'offre"	"https://www.globenewswire.com/news-release/2024/02/08/2825836/0/fr/Evaxion-r%C3%A9pond-de-nouveau-aux-exigences-du-Nasdaq-en-mati%C3%A8re-de-prix-minimum-de-l-offre.html"	"Financing Agreements"	"2024-02-08 06:20:00"	"pre_market"	6
"EVAX"	"Evaxion répond de nouveau aux exigences du Nasdaq en matière de prix minimum de l'offre"	"https://www.globenewswire.com/news-release/2024/02/08/2825836/0/fr/Evaxion-r%C3%A9pond-de-nouveau-aux-exigences-du-Nasdaq-en-mati%C3%A8re-de-prix-minimum-de-l-offre.html"	"financing_agreements"	"2024-02-08 06:20:00"	"pre_market"	6
"BNTX"	"BioNTech und Autolus schließen strategische Kollaboration zur Weiterentwicklung der Pipeline und Ausbau fortgeschrittener CAR-T-Zelltherapie-Programme"	"https://www.globenewswire.com/news-release/2024/02/08/2825809/0/de/BioNTech-und-Autolus-schlie%C3%9Fen-strategische-Kollaboration-zur-Weiterentwicklung-der-Pipeline-und-Ausbau-fortgeschrittener-CAR-T-Zelltherapie-Programme.html"	"press_releases"	"2024-02-08 05:45:00"	"pre_market"	5
"BNTX"	"BioNTech and Autolus Announce Strategic CAR-T Cell Therapy Collaboration to Advance Pipeline and Expand Late-Stage Programs"	"https://www.globenewswire.com/news-release/2024/02/08/2825809/0/en/BioNTech-and-Autolus-Announce-Strategic-CAR-T-Cell-Therapy-Collaboration-to-Advance-Pipeline-and-Expand-Late-Stage-Programs.html"	"press_releases"	"2024-02-08 05:45:00"	"pre_market"	5
"BNTX"	"BioNTech and Autolus Announce Strategic CAR-T Cell Therapy Collaboration to Advance Pipeline and Expand Late-Stage Programs"	"https://www.globenewswire.com/news-release/2024/02/08/2825809/0/en/BioNTech-and-Autolus-Announce-Strategic-CAR-T-Cell-Therapy-Collaboration-to-Advance-Pipeline-and-Expand-Late-Stage-Programs.html"	"Press releases"	"2024-02-08 05:45:00"	"pre_market"	5
"BNTX"	"BioNTech und Autolus schließen strategische Kollaboration zur Weiterentwicklung der Pipeline und Ausbau fortgeschrittener CAR-T-Zelltherapie-Programme"	"https://www.globenewswire.com/news-release/2024/02/08/2825809/0/de/BioNTech-und-Autolus-schlie%C3%9Fen-strategische-Kollaboration-zur-Weiterentwicklung-der-Pipeline-und-Ausbau-fortgeschrittener-CAR-T-Zelltherapie-Programme.html"	"Press releases"	"2024-02-08 05:45:00"	"pre_market"	5
"TOVX"	"Theriva Biologics anuncia la recomendación positiva del Comité independiente para la monitorización de los datos de Datos de VIRAGE, el ensayo clínico de fase 2b de VCN-01 en combinación con quimioterapia para el adenocarcinoma pancreático ductal metastásico"	"https://www.globenewswire.com/news-release/2024/02/07/2825629/0/es/Theriva-Biologics-anuncia-la-recomendaci%C3%B3n-positiva-del-Comit%C3%A9-independiente-para-la-monitorizaci%C3%B3n-de-los-datos-de-Datos-de-VIRAGE-el-ensayo-cl%C3%ADnico-de-fase-2b-de-VCN-01-en-combin.html"	"clinical_study"	"2024-02-07 17:53:00"	"after_hours"	17
"TOVX"	"Theriva Biologics anuncia la recomendación positiva del Comité independiente para la monitorización de los datos de Datos de VIRAGE, el ensayo clínico de fase 2b de VCN-01 en combinación con quimioterapia para el adenocarcinoma pancreático ductal metastásico"	"https://www.globenewswire.com/news-release/2024/02/07/2825629/0/es/Theriva-Biologics-anuncia-la-recomendaci%C3%B3n-positiva-del-Comit%C3%A9-independiente-para-la-monitorizaci%C3%B3n-de-los-datos-de-Datos-de-VIRAGE-el-ensayo-cl%C3%ADnico-de-fase-2b-de-VCN-01-en-combin.html"	"Clinical Study"	"2024-02-07 17:53:00"	"after_hours"	17
"YTEN"	"Yield10 Bioscience Provides an Update on its Omega-3 Camelina Program"	"https://www.globenewswire.com/news-release/2024/02/07/2825625/34378/en/Yield10-Bioscience-Provides-an-Update-on-its-Omega-3-Camelina-Program.html"	"management_statements"	"2024-02-07 17:40:00"	"after_hours"	17
"YTEN"	"Yield10 Bioscience Provides an Update on its Omega-3 Camelina Program"	"https://www.globenewswire.com/news-release/2024/02/07/2825625/34378/en/Yield10-Bioscience-Provides-an-Update-on-its-Omega-3-Camelina-Program.html"	"Management statements"	"2024-02-07 17:40:00"	"after_hours"	17
"MYCO.CN"	"Mydecine Innovations Group Receives Two Notice of Allowances from USPTO for its MYCO-005 and MYCO-006 Family of Compounds"	"https://www.globenewswire.com/news-release/2024/02/07/2825615/0/en/Mydecine-Innovations-Group-Receives-Two-Notice-of-Allowances-from-USPTO-for-its-MYCO-005-and-MYCO-006-Family-of-Compounds.html"	"Product / Services Announcement"	"2024-02-07 17:01:00"	"after_hours"	17
"MYCOF"	"Mydecine Innovations Group Receives Two Notice of Allowances from USPTO for its MYCO-005 and MYCO-006 Family of Compounds"	"https://www.globenewswire.com/news-release/2024/02/07/2825615/0/en/Mydecine-Innovations-Group-Receives-Two-Notice-of-Allowances-from-USPTO-for-its-MYCO-005-and-MYCO-006-Family-of-Compounds.html"	"Product / Services Announcement"	"2024-02-07 17:01:00"	"after_hours"	17
"MYCOF"	"Mydecine Innovations Group Receives Two Notice of Allowances from USPTO for its MYCO-005 and MYCO-006 Family of Compounds"	"https://www.globenewswire.com/news-release/2024/02/07/2825615/0/en/Mydecine-Innovations-Group-Receives-Two-Notice-of-Allowances-from-USPTO-for-its-MYCO-005-and-MYCO-006-Family-of-Compounds.html"	"product___services_announcement"	"2024-02-07 17:01:00"	"after_hours"	17
"MYCO.CN"	"Mydecine Innovations Group Receives Two Notice of Allowances from USPTO for its MYCO-005 and MYCO-006 Family of Compounds"	"https://www.globenewswire.com/news-release/2024/02/07/2825615/0/en/Mydecine-Innovations-Group-Receives-Two-Notice-of-Allowances-from-USPTO-for-its-MYCO-005-and-MYCO-006-Family-of-Compounds.html"	"product___services_announcement"	"2024-02-07 17:01:00"	"after_hours"	17
"CTKB"	"Cytek Biosciences to Participate in Upcoming Investor Conferences"	"https://www.globenewswire.com/news-release/2024/02/07/2825566/0/en/Cytek-Biosciences-to-Participate-in-Upcoming-Investor-Conferences.html"	"calendar_of_events"	"2024-02-07 16:10:00"	"after_hours"	16
"CTKB"	"Cytek Biosciences to Participate in Upcoming Investor Conferences"	"https://www.globenewswire.com/news-release/2024/02/07/2825566/0/en/Cytek-Biosciences-to-Participate-in-Upcoming-Investor-Conferences.html"	"Calendar of Events"	"2024-02-07 16:10:00"	"after_hours"	16
"TTOO"	"T2 Biosystems to Report Fourth Quarter and Full Year 2023 Financial Results and Business Updates on February 15, 2024"	"https://www.globenewswire.com/news-release/2024/02/07/2825558/32489/en/T2-Biosystems-to-Report-Fourth-Quarter-and-Full-Year-2023-Financial-Results-and-Business-Updates-on-February-15-2024.html"	"Conference Calls/ Webcasts"	"2024-02-07 16:05:00"	"after_hours"	16
"CTKB"	"Cytek Biosciences to Report Fourth Quarter and Full Year 2023 Financial Results on February 28, 2024"	"https://www.globenewswire.com/news-release/2024/02/07/2825555/0/en/Cytek-Biosciences-to-Report-Fourth-Quarter-and-Full-Year-2023-Financial-Results-on-February-28-2024.html"	"conference_calls__webcasts"	"2024-02-07 16:05:00"	"after_hours"	16
"NOTV"	"Inotiv Reports First Quarter Financial Results for Fiscal 2024 and Provides Business Update"	"https://www.globenewswire.com/news-release/2024/02/07/2825561/0/en/Inotiv-Reports-First-Quarter-Financial-Results-for-Fiscal-2024-and-Provides-Business-Update.html"	"earnings_releases_and_operating_results"	"2024-02-07 16:05:00"	"after_hours"	16
"TTOO"	"T2 Biosystems to Report Fourth Quarter and Full Year 2023 Financial Results and Business Updates on February 15, 2024"	"https://www.globenewswire.com/news-release/2024/02/07/2825558/32489/en/T2-Biosystems-to-Report-Fourth-Quarter-and-Full-Year-2023-Financial-Results-and-Business-Updates-on-February-15-2024.html"	"conference_calls__webcasts"	"2024-02-07 16:05:00"	"after_hours"	16
"NOTV"	"Inotiv Reports First Quarter Financial Results for Fiscal 2024 and Provides Business Update"	"https://www.globenewswire.com/news-release/2024/02/07/2825561/0/en/Inotiv-Reports-First-Quarter-Financial-Results-for-Fiscal-2024-and-Provides-Business-Update.html"	"Earnings Releases and Operating Results"	"2024-02-07 16:05:00"	"after_hours"	16
"CTKB"	"Cytek Biosciences to Report Fourth Quarter and Full Year 2023 Financial Results on February 28, 2024"	"https://www.globenewswire.com/news-release/2024/02/07/2825555/0/en/Cytek-Biosciences-to-Report-Fourth-Quarter-and-Full-Year-2023-Financial-Results-on-February-28-2024.html"	"Conference Calls/ Webcasts"	"2024-02-07 16:05:00"	"after_hours"	16
"IMMX"	"Immix Biopharma Awarded European Union Orphan Drug Designation for NXC-201 in AL Amyloidosis"	"https://www.globenewswire.com/news-release/2024/02/07/2825304/0/en/Immix-Biopharma-Awarded-European-Union-Orphan-Drug-Designation-for-NXC-201-in-AL-Amyloidosis.html"	"Company Announcement"	"2024-02-07 09:37:00"	"market_open"	9
"IMMX"	"Immix Biopharma Awarded European Union Orphan Drug Designation for NXC-201 in AL Amyloidosis"	"https://www.globenewswire.com/news-release/2024/02/07/2825304/0/en/Immix-Biopharma-Awarded-European-Union-Orphan-Drug-Designation-for-NXC-201-in-AL-Amyloidosis.html"	"company_announcement"	"2024-02-07 09:37:00"	"market_open"	9
"TTOO"	"U.S. Department of Health and Human Services and Steven and Alexandra Cohen Foundation Name T2 Biosystems a Phase 2 Winner in the LymeX Diagnostics Prize"	"https://www.globenewswire.com/news-release/2024/02/07/2825239/32489/en/U-S-Department-of-Health-and-Human-Services-and-Steven-and-Alexandra-Cohen-Foundation-Name-T2-Biosystems-a-Phase-2-Winner-in-the-LymeX-Diagnostics-Prize.html"	"Contests/Awards"	"2024-02-07 09:00:00"	"pre_market"	9
